Deals & Cases
Agenus Inc. acquires 4-Antibody AGLenz & Staehelin assisted Nasdaq listed Agenus Inc., a biotechnology company, headquartered in the US, acquiring the entire share capital of 4-Antibody AG, a privately held Swiss-based biopharmaceutical company. Under the terms of the agreement, Agenus has acquired all of the outstanding stock of 4-Antibody for an initial payment of USD 10 million in shares of Agenus common stock, plus additional contingent payments, payable in cash or Agenus common stock, that may exceed USD 40 million based on the combined company achieving certain milestones. The transaction closed on February 12, 2014. The Lenz & Staehelin team consisted of Andreas Rötheli and Felix Gey Jauffret (both Corporate and M&A).